-
![Ironwood Cover_2016]( "Where Are They Now? Ironwood Pharmaceuticals")
Where Are They Now? Ironwood Pharmaceuticals10/31/2024Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
-
![Dr-Stella-Sarraf_Spinogenix]( "Companies To Watch: Spinogenix")
Companies To Watch: Spinogenix10/18/2024Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.
-
![Alternative Alzheimers Therapy_Annovis_Getty_1455906752]( "Annovis Bio: Against The Grain In Alzheimer's Disease")
Annovis Bio: Against The Grain In Alzheimer's Disease10/1/2024From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s independent-minded approach to neurodegenerative disease could shake up the treatment landscape.
-
![Alicia Zhou]( "New Leadership At The Cancer Research Institute")
New Leadership At The Cancer Research Institute9/27/2024Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year old cancer research nonprofit into the future.
-
![Steven Kelly_300CMYK]( "Where Are They Now? Carisma Therapeutics")
Where Are They Now? Carisma Therapeutics9/22/2024In three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original CAR-Macrophage candidate, in favor of CAR-Monocyte therapies. Carisma expects to release CT-0525 Phase 1 data by the end of 2024.
-
![Alex Martinez]( "A Systems Approach To Parkinson's Disease")
A Systems Approach To Parkinson's Disease8/30/2024New research into Parkinson's disease is strengthening the connection between an unhealthy gut and brain disorders.
-
![Greg_Kunst]( "Companies To Watch: Aurion Biotech")
Companies To Watch: Aurion Biotech8/30/2024Aurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases.
-
![Google AI image_Getty-1488113402]( "Google Life Sciences Leader Talks AI Opportunities And 'Watch Outs' For Biopharma")
Google Life Sciences Leader Talks AI Opportunities And 'Watch Outs' For Biopharma8/29/2024Shweta Maniar, Google’s global market leader for life sciences, spoke with Life Science Leader about how large and small biopharmaceutical companies are using AI to lower costs and expedite timelines.
-
![Rachel Haurwitz]( "Where Are They Now? Caribou Biosciences")
Where Are They Now? Caribou Biosciences8/5/2024Caribou Biosciences is gunning for a Phase 3 pivotal trial start in 2025 for lead candidate CB-010, after cutting its CAR-NK preclinical activities to focus exclusively on developing CB-010 and two additional allogeneic CAR-T therapies.
Ben Comer
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.